Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Dust grains fall from Saturn's D-ring into its equatorial upper atmosphere.

Mitchell DG, Perry ME, Hamilton DC, Westlake JH, Kollmann P, Smith HT, Carbary JF, Waite JH Jr, Perryman R, Hsu HW, Wahlund JE, Morooka MW, Hadid LZ, Persoon AM, Kurth WS.

Science. 2018 Oct 5;362(6410). pii: eaat2236. doi: 10.1126/science.aat2236.

PMID:
30287633
2.

A radiation belt of energetic protons located between Saturn and its rings.

Roussos E, Kollmann P, Krupp N, Kotova A, Regoli L, Paranicas C, Mitchell DG, Krimigis SM, Hamilton D, Brandt P, Carbary J, Christon S, Dialynas K, Dandouras I, Hill ME, Ip WH, Jones GH, Livi S, Mauk BH, Palmaerts B, Roelof EC, Rymer A, Sergis N, Smith HT.

Science. 2018 Oct 5;362(6410). pii: eaat1962. doi: 10.1126/science.aat1962.

PMID:
30287631
3.

Monitoring cryptic amphibians and reptiles in a Florida state park.

Engeman RM, Meshaka WE Jr, Severson R, Severson MA, Kaufman G, Groninger NP, Smith HT.

Environ Sci Pollut Res Int. 2016 Apr;23(7):7032-7. doi: 10.1007/s11356-015-6028-8. Epub 2016 Jan 6.

PMID:
26739988
4.

Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Kerr C, Lloyd EJ, Kosmas CE, Smith HT, Cooper JA, Johnston K, McIntosh E, Lloyd AJ.

Qual Life Res. 2016 Jun;25(6):1505-15. doi: 10.1007/s11136-015-1187-0. Epub 2015 Dec 1.

PMID:
26627224
5.

A Systematic Review and Network Meta-Analysis of Pharmacological Therapies Used for Patients with Advanced Parkinson's Disease.

Ren S, Cooper K, Cooper JA, Smith HT, Shaikh S.

Value Health. 2014 Nov;17(7):A390. doi: 10.1016/j.jval.2014.08.856. Epub 2014 Oct 26. No abstract available.

6.

Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study.

Jones S, Castell C, Goday A, Smith HT, Nicolay C, Simpson A, Salaun-Martin C.

Clinicoecon Outcomes Res. 2012;4:383-93. doi: 10.2147/CEOR.S36148. Epub 2012 Dec 20.

7.

Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE.

Liebl A, Jones S, Goday A, Benroubi M, Castell C, Haupt A, Nicolay C, Smith HT.

Diabetes Ther. 2012 Nov;3(1):9. doi: 10.1007/s13300-012-0009-4. Epub 2012 Aug 28.

8.
9.

A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care.

Blak BT, Smith HT, Hards M, Maguire A, Gimeno V.

Diabet Med. 2012 Aug;29(8):e191-8. doi: 10.1111/j.1464-5491.2012.03694.x.

PMID:
22507537
10.

Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin.

Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T.

Diabet Med. 2012 Jul;29(7):e13-20. doi: 10.1111/j.1464-5491.2012.03586.x.

PMID:
22268988
11.

Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects.

Duan J, Chen J, Yin Q, Karan R, Meiser K, Smith HT, Sunkara G.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):33-43.

PMID:
22192643
12.

An automation-assisted generic approach for biological sample preparation and LC-MS/MS method validation.

Zhang J, Wei S, Ayres DW, Smith HT, Tse FL.

Bioanalysis. 2011 Sep;3(17):1975-86. doi: 10.4155/bio.11.178.

PMID:
21899506
13.

Quantitative analysis of NIM811, a cyclophilin inhibitor, in human dried blood spots using liquid chromatography-tandem mass spectrometry.

Li W, Williams SM, Smith HT, Tse FL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2376-82. doi: 10.1016/j.jchromb.2011.06.030. Epub 2011 Jun 26.

PMID:
21783438
14.

Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma.

Li W, Lin H, Smith HT, Tse FL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 1;879(21):1927-33. doi: 10.1016/j.jchromb.2011.05.012. Epub 2011 May 14.

PMID:
21680264
15.

An investigation of incurred human urine sample reanalysis failure.

Fu Y, Li W, Smith HT, Tse FL.

Bioanalysis. 2011 May;3(9):967-72. doi: 10.4155/bio.11.65.

PMID:
21545344
16.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
17.

Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries.

Liebl A, Jones S, Benroubi M, Castell C, Goday A, Aline Charles M, Smith HT, Nicolay C, Simpson A.

Curr Med Res Opin. 2011 May;27(5):887-95. doi: 10.1185/03007995.2011.555755. Epub 2011 Feb 22.

PMID:
21341946
18.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ.

ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.

PMID:
21090814
19.

Quantitative determination of BAF312, a S1P-R modulator, in human urine by LC-MS/MS: prevention and recovery of lost analyte due to container surface adsorption.

Li W, Luo S, Smith HT, Tse FL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 15;878(5-6):583-9. doi: 10.1016/j.jchromb.2009.12.031. Epub 2010 Jan 4.

PMID:
20097141
20.

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ.

Diabet Med. 2009 Aug;26(8):803-14. doi: 10.1111/j.1464-5491.2009.02775.x. Review.

21.

Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.

Xin Z, Zhao H, Serby MD, Liu B, Liu M, Szczepankiewicz BG, Nelson LT, Smith HT, Suhar TS, Janis RS, Cao N, Camp HS, Collins CA, Sham HL, Surowy TK, Liu G.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4298-302. doi: 10.1016/j.bmcl.2008.06.088. Epub 2008 Jun 28.

PMID:
18632269
22.

Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.

Liu G, Lynch JK, Freeman J, Liu B, Xin Z, Zhao H, Serby MD, Kym PR, Suhar TS, Smith HT, Cao N, Yang R, Janis RS, Krauser JA, Cepa SP, Beno DW, Sham HL, Collins CA, Surowy TK, Camp HS.

J Med Chem. 2007 Jun 28;50(13):3086-100. Epub 2007 May 27.

PMID:
17530838
23.
24.

Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.

Zhao H, Serby MD, Smith HT, Cao N, Suhar TS, Surowy TK, Camp HS, Collins CA, Sham HL, Liu G.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3388-91. Epub 2007 Apr 5.

PMID:
17434733
25.

Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry.

Li W, Luo S, Li S, Athill L, Wu A, Ray T, Zhou W, Ke J, Smith HT, Tse FL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):57-68. Epub 2006 Sep 7.

PMID:
16962398
26.

Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.

Schuurman HJ, Smith HT, Cozzi E.

Toxicology. 2005 Sep 15;213(1-2):1-12.

PMID:
15970369
27.

Composition and dynamics of plasma in Saturn's magnetosphere.

Young DT, Berthelier JJ, Blanc M, Burch JL, Bolton S, Coates AJ, Crary FJ, Goldstein R, Grande M, Hill TW, Johnson RE, Baragiola RA, Kelha V, McComas DJ, Mursula K, Sittler EC, Svenes KR, Szegö K, Tanskanen P, Thomsen MF, Bakshi S, Barraclough BL, Bebesi Z, Delapp D, Dunlop MW, Gosling JT, Furman JD, Gilbert LK, Glenn D, Holmlund C, Illiano JM, Lewis GR, Linder DR, Maurice S, McAndrews HJ, Narheim BT, Pallier E, Reisenfeld D, Rymer AM, Smith HT, Tokar RL, Vilppola J, Zinsmeyer C.

Science. 2005 Feb 25;307(5713):1262-6.

28.

Reference values for clinical chemistry and clinical hematology parameters in cynomolgus monkeys.

Schuurman HJ, Smith HT.

Xenotransplantation. 2005 Jan;12(1):72-5.

PMID:
15598276
29.

Reference values for clinical chemistry and clinical hematology parameters in baboons.

Schuurman HJ, Smith HT, Cozzi E.

Xenotransplantation. 2004 Nov;11(6):511-6.

PMID:
15479460
30.
31.

Pharmacokinetics of nateglinide in renally impaired diabetic patients.

Devineni D, Walter YH, Smith HT, Lee JS, Prasad P, McLeod JF.

J Clin Pharmacol. 2003 Feb;43(2):163-70.

PMID:
12616669
32.

Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.

Clampit JE, Meuth JL, Smith HT, Reilly RM, Jirousek MR, Trevillyan JM, Rondinone CM.

Biochem Biophys Res Commun. 2003 Jan 10;300(2):261-7.

PMID:
12504077
33.

Integrating nonindigenous aquatic plant control with protection of snail kite nests in Florida.

Rodgers JA Jr, Smith HT, Thayer DD.

Environ Manage. 2001 Jul;28(1):31-7.

PMID:
11436998
34.
35.

RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis.

Doyle RL, Hertz MI, Dunitz JM, Loyd JE, Stecenko AA, Wong RL, Chappell KA, Brazelton T, Kovarik JM, Appeldingemanse S, Dou L, Smith HT, Tudor D, Morris RE.

J Heart Lung Transplant. 2001 Mar;20(3):330-9.

PMID:
11257560
36.

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

Trevillyan JM, Chiou XG, Ballaron SJ, Tang QM, Buko A, Sheets MP, Smith ML, Putman CB, Wiedeman P, Tu N, Madar D, Smith HT, Gubbins EJ, Warrior UP, Chen YW, Mollison KW, Faltynek CR, Djurić SW.

Arch Biochem Biophys. 1999 Apr 1;364(1):19-29.

PMID:
10087161
37.

Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation.

Cooney GF, Dunn SP, Sommerauer J, Lindsay C, McDiarmid S, Choc MG Jr, Smith HT, Chang CT, Wong RL.

Liver Transpl Surg. 1999 Mar;5(2):112-8.

38.

Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.

Choc MG, Mueller EA, Robinson WT, Kumle A, Smith HT, Charnick SB.

Transplant Proc. 1998 Aug;30(5):1664-5. No abstract available.

PMID:
9723234
39.

Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.

Dunn S, Cooney G, Sommerauer J, Lindsay C, McDiarmid S, Wong RL, Chang CT, Smith HT, Choc MG Jr.

Transplantation. 1997 Jun 27;63(12):1762-7.

PMID:
9210501
40.

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD.

J Clin Pharmacol. 1997 Feb;37(2):123-8.

PMID:
9055138
41.

Use of Neoral in pediatric renal transplantation.

Ettenger RE, Smith HT, Kaiser B, Cooney GF, Summerauer J, Alexander S, Moulton LT, Choc MG, Wong RL.

Transplant Proc. 1996 Aug;28(4):2257-8. No abstract available.

PMID:
8769217
42.

Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation.

Kovarik JM, Mueller EA, Kallay Z, Smith HT, Lison AE, Arns W, Renner E.

J Clin Pharmacol. 1995 Dec;35(12):1136-43.

PMID:
8750363
43.

Pharmacokinetics of fluvastatin and specific drug interactions.

Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT.

Am J Hypertens. 1993 Nov;6(11 Pt 2):375S-382S.

PMID:
8297546
44.

High-performance liquid chromatographic method for the determination of fluvastatin in human plasma.

Kalafsky G, Smith HT, Choc MG.

J Chromatogr. 1993 May 5;614(2):307-13.

PMID:
8314944
45.

Hypertension and the kidney.

Smith HT.

Am J Hypertens. 1993 Apr;6(4):119S-122S. Review. No abstract available.

PMID:
8507439
46.

Activation-induced ubiquitination of the T cell antigen receptor.

Cenciarelli C, Hou D, Hsu KC, Rellahan BL, Wiest DL, Smith HT, Fried VA, Weissman AM.

Science. 1992 Aug 7;257(5071):795-7.

PMID:
1323144
47.

Overexpression of three ubiquitin genes in mouse epidermal tumors is associated with enhanced cellular proliferation and stress.

Finch JS, St John T, Krieg P, Bonham K, Smith HT, Fried VA, Bowden GT.

Cell Growth Differ. 1992 May;3(5):269-78. Erratum in: Cell Growth Differ 1992 Aug;3(8):566.

48.

Electrolytes in the epidemiology, pathophysiology, and treatment of hypertension.

Smith HT.

Prim Care. 1991 Sep;18(3):545-57. Review.

PMID:
1946787
49.

Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease.

Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM.

Brain Res. 1991 Jan 18;539(1):11-8.

PMID:
1849776
50.

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.

Tse FL, Smith HT, Ballard FH, Nicoletti J.

Biopharm Drug Dispos. 1990 Aug-Sep;11(6):519-31.

PMID:
2207302

Supplemental Content

Loading ...
Support Center